ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation LNP delivery technology that enables delivery to target organs and tissues beyond the liver. The key advances of the SORT LNPs relative to all other LNPs that have been used previously are that SORT LNPs can package a wide range of nucleic acid cargoes and deliver them to intended cellular targets to enable a wide range of therapeutic uses. In particular, the SORT LNPs can be “tuned” to deliver payloads to intended target organs, tissues, and cells beyond liver hepatocytes (which is where conventional LNPs go when administered into the blood). This is done by modulating the interaction between LNPs and plasma proteins such as Apolipoprotein E (ApoE) and does not require the addition of specific targeting ligands. The addition of a biochemically distinct SORT lipid of the right chemical nature and in the right relative amount, is the main factor that is used to tune the SORT LNP biodistribution characteristics. It has not been possible to tune traditional LNPs in this way, which is why they have been limited to IV delivery to the liver and ex vivo engineering of cells. The addition of SORT lipids has also been found to enhance LNP packaging versatility, enabling multiple types of nucleic acids, and even proteins, to be delivered together in the same LNP. Furthermore, SORT lipids have been found to significantly enhance potency for delivery to target cells, and to further tune the local cell tropism in target organs and tissues. For more information, visit www.recodetx.com and follow us on LinkedIn.